The estimated Net Worth of Marc Semigran is at least $810 mil dollars as of 4 September 2018. Marc Semigran owns over 45,000 units of MyoKardia stock worth over $809,676 and over the last 8 years Marc sold MYOK stock worth over $0.
Marc has made over 1 trades of the MyoKardia stock since 2018, according to the Form 4 filled with the SEC. Most recently Marc exercised 45,000 units of MYOK stock worth $717,750 on 4 September 2018.
The largest trade Marc's ever made was exercising 45,000 units of MyoKardia stock on 4 September 2018 worth over $717,750. On average, Marc trades about 5,000 units every 0 days since 2016. As of 4 September 2018 Marc still owns at least 3,600 units of MyoKardia stock.
You can see the complete history of Marc Semigran stock trades at the bottom of the page.
Marc's mailing address filed with the SEC is 333 Allerton Ave, South San Francisco, CA 94080, USA.
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr, eRock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
MyoKardia executives and other stock owners filed with the SEC include: